Delayed Cerebral Ischemia & Cerebral Vasospasm

ABPN Neurocritical Care Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Neurologic Examination & Coma Assessment in the ICU

Current Examination, Blueprint & Preparation Neurologic Examination in Critically Ill Patients Coma Evaluation & Consciousness Alterations Delirium & Toxic-Metabolic Encephalopathy in the ICU

2 Chapter 2: Cerebral Physiology & Intracranial Dynamics

Cerebral Blood Flow, Metabolism & Autoregulation Intracranial Pressure & Compliance Cerebral Edema & Herniation Syndromes

3 Chapter 3: Intracranial Hypertension & Cerebral Perfusion Management

Tiered ICP Management Protocols Hyperosmolar Therapy & Fluid Management Advanced & Refractory ICP Interventions

4 Chapter 4: Airway, Mechanical Ventilation & Pulmonary ICU Management

Emergency Airway Management & Neuro-Intubation Mechanical Ventilation Strategies in Acute Brain Injury Tracheostomy & Ventilator Weaning in Neurocritical Care Pulmonary Complications in the Neuro-ICU Obstructive Lung Disease, Pulmonary Hypertension & Bronchoscopy

5 Chapter 5: Hemodynamics, Shock & Cardiovascular Management

Hemodynamic Monitoring & Blood Pressure Targets Vasoactive Agents: Inotropes, Vasopressors & Antihypertensives Cardiac Complications of Brain Injury

6 Chapter 6: Neuropharmacology, Analgesia & Sedation

ICU Sedation & Analgesia Neuromuscular Blockade & Monitoring Propofol Infusion Syndrome & Drug Toxicities Antiseizure Drug Pharmacology in the ICU

7 Bleeding, Thrombosis & Hematologic Emergencies

Warfarin & Heparin Reversal Direct Oral Anticoagulant (DOAC) Reversal Antiplatelet Management & Platelet Dysfunction Venous Thromboembolism Prophylaxis & Management Transfusion, Coagulopathy, TMA & Cellular-Therapy Neurotoxicity

8 Chapter 8: Systemic ICU Care, Fluids, Electrolytes & Endocrine

Hyponatremia & Osmoregulation: SIADH vs Cerebral Salt Wasting Diabetes Insipidus, Hypernatremia & Endocrine Crises Critical Care Prophylaxis, Nutrition & Infection Prevention

9 Systemic Trauma & Environmental Injury

Polytrauma, Chest Injury & Abdominal Hemorrhage Burns, Electrical Injury & Hanging

10 Cardiac Emergencies & Mechanical Support

IABP, Ventricular Devices & ECMO Acute Coronary, Valvular, Rhythm & Aortic Emergencies

11 Kidney Injury, Acid–Base & Renal Replacement

Acute Kidney Injury & Renal Drug Clearance Acid–Base Disorders, Electrolytes & Renal Replacement

12 Systemic Infection & Endocrine Emergencies

Sepsis, Endocarditis & Antimicrobial Principles Thyroid, Adrenal & Dysglycemic Emergencies

13 Gastrointestinal & Hepatic Emergencies

Acute Abdomen, GI Bleeding & Abdominal Compartment Syndrome Acute Liver Failure, Cirrhosis & Hepatic Drug Effects

14 Chapter 9: Neuroimaging in the Neuro-ICU

Non-Contrast CT & CT Angiography CT Perfusion & Advanced Perfusion Imaging Magnetic Resonance Imaging in Critical Illness

15 Chapter 10: Electrophysiology & Neuromonitoring

Continuous EEG & ACNS Standardized Critical Care Terminology Invasive Neuromonitoring: ICP & External Ventricular Drains Multimodal Monitoring: PbtO2, Microdialysis & Transcranial Doppler

16 Angiography, Electrodiagnosis & CSF Analysis

Conventional Angiography & Cranial–Spinal Shunts EMG, Nerve Conduction & Acute Muscle Disease CSF Analysis: Infection, Inflammation & Hemorrhage

17 Chapter 11: Bedside Procedures, Ultrasound & Death by Neurologic Criteria

Critical Care Procedural Skills Critical Care Ultrasound & Echocardiography Determination of Death by Neurologic Criteria

18 Chapter 12: Acute Ischemic Stroke & Reperfusion Therapies

Acute Ischemic Stroke Management & Thrombolysis Endovascular Thrombectomy & Large Vessel Occlusion Malignant Hemispheric & Cerebellar Infarction

19 Chapter 13: Spontaneous Intracerebral Hemorrhage & Intraventricular Hemorrhage

Acute Intraparenchymal Hemorrhage Management Intraventricular Hemorrhage & Hydrocephalus Surgical Evacuation & Minimally Invasive Surgery in ICH

20 Chapter 14: Aneurysmal Subarachnoid Hemorrhage & Delayed Cerebral Ischemia

Aneurysmal Subarachnoid Hemorrhage: Acute Resuscitation & Securing Delayed Cerebral Ischemia & Cerebral Vasospasm Non-Aneurysmal Subarachnoid Hemorrhage & Vascular Malformations

21 Venous, Spinal & Traumatic Vascular Disease

Cerebral Venous Thrombosis & Spinal Cord Infarction Traumatic Dissection, Carotid–Cavernous Fistula & Penetrating Injury

22 Chapter 15: Traumatic Brain & Spinal Cord Injury

Severe Traumatic Brain Injury & Contusions Acute Traumatic Spinal Cord Injury & Neurogenic Shock Spine Trauma, Fractures & Cord Syndromes

23 Chapter 16: Status Epilepticus, Seizures & Neuromuscular Emergencies

Status Epilepticus: Convulsive & Non-Convulsive Refractory & Super-Refractory Status Epilepticus Acute Neuromuscular Respiratory Failure

24 Chapter 17: Post-Cardiac Arrest Care, CNS Infections & Encephalitis

Targeted Temperature Management & Post-Cardiac Arrest Care Post-Cardiac Arrest Neuroprognostication Acute CNS Infections, Encephalitis & Inflammatory Emergencies

25 Neuroinflammation & Neurooncology

Fulminant Demyelination & Autoimmune Encephalitis Brain, Spinal & Leptomeningeal Cancer Emergencies

26 Pregnancy, Transplantation & Pediatric Care

Pregnancy, Postpartum & Post-Transplant Neurologic Care Pediatric Neurocritical Care

27 Chapter 18: Neurosurgical & Perioperative Emergencies

Postoperative Neurosurgical Complications Device Complications: EVDs, Shunts & ICP Monitors Cerebral Hyperperfusion Syndrome & Post-Interventional Emergencies

28 Chapter 19: Ethics, Palliative Care & Organ Donation in the Neuro-ICU

Communication, Surrogate Decision-Making & Conflict Resolution Neuroprognostication Ethics, Withdrawal of Life Support & Palliative Care Organ Donation & Management of the Deceased Donor

Delayed Cerebral Ischemia & Cerebral Vasospasm

Key Takeaways Explain This Topic AI

DCI and angiographic vasospasm are related but distinct; exclude alternative causes of a new neurologic deficit.

Enteral nimodipine improves outcomes after aSAH, with treatment adjusted for clinically significant hemodynamic effects.

MCA velocities and the Lindegaard ratio support surveillance but do not independently diagnose every ischemic event.

Maintain euvolemia; selected pressure elevation and endovascular rescue can be appropriate for symptomatic DCI.

Routine prophylactic hypervolemia, hemodilution, statins, and IV magnesium do not have a recommended outcome-improving role.

Last updated: October 2026

Delayed Cerebral Ischemia & Cerebral Vasospasm

Delayed cerebral ischemia ( D C I DCI D C I ) remains the foremost cause of secondary neurological morbidity and mortality in patients who survive initial aneurysmal subarachnoid hemorrhage ( a S A H aSAH a S A H ). Historically equated solely with luminal narrowing of proximal conducting arteries ("cerebral vasospasm"), contemporary neurocritical care recognizes DCI as a multifaceted neurovascular syndrome that demands structured multimodality monitoring and aggressive, stage-specific interventions.

Pathophysiological Distinction: Vasospasm vs DCI

A critical conceptual distinction exists between angiographic vasospasm and delayed cerebral ischemia:

Feature Angiographic Vasospasm Delayed Cerebral Ischemia (DCI)

Definition Arterial narrowing demonstrated on digital subtraction angiography ( D S A DSA D S A ), C T A CTA CT A , or M R A MRA MR A Clinical syndrome of focal neurological impairment or cognitive decline lasting ≥ 1 hour \ge 1\text{ hour} ≥ 1 hour

Incidence Observed in up to 70 % 70\% 70% of all aSAH patients Manifests clinically in 30 – 40 % 30\text{--}40\% 30 – 40% of patients

Temporal Profile Onset day 3–4 post-bleed; peak severity days 7–10 ; resolution by day 14–21 Typically develops between post-bleed days 4 and 14

Clinical Impact Frequently asymptomatic if adequate collateral circulation exists Directly produces secondary cerebral infarction, disability, and death

Diagnostic Criteria Topographic luminal reduction > 33 – 50 % > 33\text{--}50\% > 33 – 50% of parent vessel diameter Drop in GCS ≥ 2 \ge 2 ≥ 2 points or new focal deficit (motor weakness, aphasia, neglect) not attributable to other causes

The Multifactorial Mechanisms of DCI

Clinical trials demonstrating that drugs reversing macrovascular vasospasm (e.g., clazosentan, an endothelin receptor antagonist) failed to improve functional neurological outcomes confirmed that large-vessel narrowing is only one component of DCI. DCI is driven by four synergistic microvascular and cellular derangements:

Microvascular Constriction & Autoregulatory Failure: Hemoglobin degradation products scavenge endothelial nitric oxide ( N O NO NO ) and upregulate endothelin-1, inducing profound constriction of parenchymal resistance arterioles ( < 100 μ m < 100\,\mu\text{m} < 100 μ m ) that are invisible on conventional angiography.

Microvascular Thrombosis: Subarachnoid blood triggers von Willebrand factor release, platelet activation, and localized microvascular microthrombi formation, causing focal capillary plugging and downstream ischemia.

Cortical Spreading Depolarization ( C S D CSD CS D ): Waves of massive, slowly propagating ( 2 – 5 mm/min 2\text{--}5\text{ mm/min} 2 – 5 mm/min ) cellular depolarization sweep across the cerebral cortex. In the setting of compromised neurovascular coupling, CSD triggers paradoxical vasoconstriction ("spreading ischemia") rather than compensatory hyperemia, exhausting cellular ATP reserves.

Neuroinflammation & Blood-Brain Barrier ( B B B BBB BBB ) Breakdown: Infiltration of subarachnoid spaces by neutrophils and microglia generates reactive oxygen species ( R O S ROS ROS ), lipid peroxidation, and endothelial swelling.

Nimodipine Neuroprotection & Hemodynamic Optimization

Oral nimodipine is the only pharmacological agent proven in randomized clinical trials to improve functional neurological outcomes and reduce cerebral infarction in aSAH.

Clinical Evidence: The BANT Trial

The landmark British Aneurysm Nimodipine Trial (BANT) and subsequent meta-analyses established that enteral nimodipine:

• Reduces the incidence of cerebral infarction by 34 % 34\% 34%
• Reduces poor neurological outcomes and death by 40 % 40\% 40%

Does NOT prevent or reduce the incidence of large-vessel angiographic vasospasm. Nimodipine's efficacy is mediated by cellular neuroprotection (inhibition of L-type calcium channels attenuating intracellular calcium overload and excitotoxicity) and microvascular dilation.

Administration Guidelines & Troubleshooting Hypotension

Standard Dosing: 60 mg 60\text{ mg} 60 mg enterally (or via NG/OG tube) every 4 hours for the usual 21-day course, with clinical adjustments when needed (Class 1, Level A).

Route Warning: Intravenous nimodipine is strictly prohibited in the United States; inadvertent IV injection of oral nimodipine capsules causes refractory systemic hypotension, cardiovascular collapse, and death.

Warning

Give enteral nimodipine consistently when feasible. Manage treatable hypotension and consider dose adjustment under protocol, but significant pressure instability may require temporary interruption. Do not sacrifice systemic or cerebral perfusion to an absolute never-hold rule. Never inject an oral nimodipine product intravenously.

Surveillance Neuromonitoring Modalities

Early detection of impending DCI prior to irreversible infarction is the central goal of ICU surveillance. [ Daily aSAH Neuromonitoring Protocol ]

• │
• ┌────────────┼────────────┐
• ▼ ▼ ▼
• [ Serial Neuro ] [ Daily TCD ] [ Continuous EEG ]
• Hourly GCS • MCA MFV • Alpha-Delta Ratio
• Focal deficit trends (ADR) decline
• NIHSS changes • Lindegaard • Review raw EEG
• Ratio with trends
• │
• ▼
• [ Neurologic Decline or High-Risk Biomarkers ]
• │
• ▼
• [ Multimodal Advanced Neuroimaging / Invasive Probes ]
• CT Perfusion: Tmax > 6.0 s / MTT prolongation
• Invasive PbtO2: Tissue PO2 < 20 mmHg (critical < 10 mmHg)
• Microdialysis: Lactate/Pyruvate Ratio (LPR) > 40
• Transcranial Doppler ( T C D TCD TC D ) & The Lindegaard Ratio

TCD provides non-invasive, bedside velocity assessments of basal intracranial arteries:

MCA Mean Flow Velocity ( M F V MFV MF V ):

• Normal: < 120 cm/s < 120\text{ cm/s} < 120 cm/s
• Mild vasospasm: 120 – 149 cm/s 120\text{--}149\text{ cm/s} 120 – 149 cm/s
• Moderate vasospasm: 150 – 199 cm/s 150\text{--}199\text{ cm/s} 150 – 199 cm/s

Severe vasospasm: ≥ 200 cm/s \ge 200\text{ cm/s} ≥ 200 cm/s (or rapid daily increase > 50 cm/s > 50\text{ cm/s} > 50 cm/s per 24 hours)

The Lindegaard Ratio ( L R LR L R ): Differentiates true macrovascular vasospasm from systemic hyperdynamic flow (hyperemia induced by hypertension or inotropes): Lindegaard Ratio ( L R ) = MCA Mean Flow Velocity Extracranial Internal Carotid Artery ( e I C A ) Mean Flow Velocity \text{Lindegaard Ratio } (LR) = \frac{\text{MCA Mean Flow Velocity}}{\text{Extracranial Internal Carotid Artery } (eICA) \text{ Mean Flow Velocity}} Lindegaard Ratio ( L R ) = Extracranial Internal Carotid Artery ( e I C A ) Mean Flow Velocity MCA Mean Flow Velocity ​

L R < 3.0 LR < 3.0 L R < 3.0 : Hyperdynamic flow / hyperemia (elevated MCA velocity is driven by systemic cardiac output).

L R = 3.0 – 6.0 LR = 3.0\text{--}6.0 L R = 3.0 – 6.0 : Mild-to-moderate true macrovascular vasospasm.

L R > 6.0 LR > 6.0 L R > 6.0 : Severe macrovascular vasospasm.

Basilar Artery: Evaluated using the basilar-to-extracranial-vertebral velocity ratio (Soustiel/Sviri approach) (Basilar MFV / Extracranial Vertebral MFV); a ratio > 3.0 > 3.0 > 3.0 denotes true basilar artery vasospasm.

Advanced Imaging & Invasive Neuromonitoring

Continuous EEG ( c E E G cEEG c EEG ): In comatose or deeply sedated patients where clinical examination is uninformative, cEEG identifies ischemia hours before infarction. The primary biomarker is a progressive decrease in the Alpha-Delta Ratio ( A D R ADR A D R ) or total spectral power envelope decline.

CT Perfusion ( C T P CTP CTP ): Quantitative perfusion maps identify hypoperfused penumbra. Prolongation of T max ⁡ > 6.0 seconds T_{\max} > 6.0\text{ seconds} T m a x ​ > 6.0 seconds or Mean Transit Time ( M T T > 5.5 – 6.0 seconds MTT > 5.5\text{--}6.0\text{ seconds} MTT > 5.5 – 6.0 seconds ) with preserved or elevated Cerebral Blood Volume ( C B V CBV CB V ) delineates salvageable tissue at risk of DCI.

Invasive Brain Tissue Oxygenation ( P b t O 2 PbtO_2 P b t O 2 ​ ): A parenchymal polarographic probe measures local oxygen tension. P b t O 2 < 20 mmHg PbtO_2 < 20\text{ mmHg} P b t O 2 ​ < 20 mmHg reflects tissue hypoxia; P b t O 2 < 10 mmHg PbtO_2 < 10\text{ mmHg} P b t O 2 ​ < 10 mmHg indicates critical cellular ischemia requiring immediate physiological escalation.

Cerebral Microdialysis: Measures local metabolic crisis. A Lactate-to-Pyruvate Ratio ( L P R LPR L PR ) > 40 > 40 > 40 combined with extracellular glucose < 0.8 mmol/L < 0.8\text{ mmol/L} < 0.8 mmol/L indicates anaerobic glycolysis and secondary mitochondrial uncoupling.

• Medical Management: The Death of "Triple-H" & Modern Hemodynamics
• Why Historical "Triple-H" Is Obsolete

For decades, empiric "Triple-H" therapy (hypervolemia, hemodilution, hypertension) was dogma. Modern multicenter trials revealed that two of the three components are overtly harmful:

Hypervolemia: Prophylactic hypervolemia does not improve cerebral blood flow or functional outcomes. Instead, fluid overloading produces a 15 – 25 % 15\text{--}25\% 15 – 25% incidence of severe complications: cardiogenic pulmonary edema, myocardial infarction, iatrogenic hyponatremia, and exacerbation of cerebral edema.

Hemodilution: While reducing blood viscosity, intentional hemodilution to hematocrit < 30 % < 30\% < 30% directly diminishes arterial oxygen content ( C a O 2 = 1.34 × [ H b ] × S a O 2 + 0.003 × P a O 2 CaO_2 = 1.34 \times [Hb] \times SaO_2 + 0.003 \times PaO_2 C a O 2 ​ = 1.34 × [ H b ] × S a O 2 ​ + 0.003 × P a O 2 ​ ), impairing total cerebral oxygen delivery ( D O 2 = C B F × C a O 2 DO_2 = CBF \times CaO_2 D O 2 ​ = CBF × C a O 2 ​ ) despite increased blood flow.

The Contemporary Paradigm: Euvolemia + Induced Hypertension

Parameter Historical Triple-H Modern Guideline-Directed Standard

Volume Target Hypervolemia ( C V P > 10 – 12 mmHg CVP > 10\text{--}12\text{ mmHg} C V P > 10 – 12 mmHg , positive fluid balance) Strict Euvolemia (neutral fluid balance, isotonic crystalloids)

Hematocrit Target Hemodilution (Hct 28 – 32 % 28\text{--}32\% 28 – 32% ) Avoid intentional hemodilution; individualize transfusion from clinical context and evidence

Blood Pressure Target Empiric hypertension across all patients Targeted Induced Hypertension applied only upon onset of clinical DCI

Evaluate and Treat Symptomatic DCI

Assess a new deficit promptly for rebleeding, hydrocephalus, seizure, metabolic disturbance, infection, and other causes. Do not assume that a high TCD velocity alone proves symptomatic DCI. Maintain euvolemia rather than prophylactic hypervolemia or hemodilution.

In symptomatic DCI after aneurysm treatment, selected pressure elevation can be beneficial. Norepinephrine is commonly used, but a single agent or exact SBP increment is not mandated by robust comparative evidence. Titrate to the examination and perfusion response while monitoring cardiac and pulmonary tolerance. Do not wait an arbitrary one or two hours to escalate if the patient is deteriorating.

CTA, perfusion imaging, EEG trends, and selected invasive monitoring support the assessment. CTP stroke thresholds are not universally validated DCI cutoffs. Endovascular vasodilators or angioplasty may be reasonable in selected severe vasospasm. The choice, timing, and risk depend on vessel anatomy and clinical response, not a fixed clock or one monitoring number.

Endovascular Rescue Therapies

Patients with DCI refractory to induced hypertension, or those in whom induced hypertension is contraindicated (e.g., severe heart failure, acute myocardial infarction), require emergent catheter-directed rescue therapy.

Modality Transluminal Balloon Angioplasty Intra-Arterial (IA) Vasodilator Infusion

Target Vasculature Proximal, large-caliber vessels (cavernous/supraclinoid ICA, M1, A1, basilar trunk, P1) Distal, branch vessels (M2/M3, A2/A3, P2/P3) and diffuse microvascular beds

Mechanism Mechanical disruption of adventitial and medial collagenous lattice Pharmacological smooth muscle relaxation via L-type calcium blockade or PDE-3 inhibition

Agents Used Non-compliant or compliant microballoons Nicardipine ( 2.5 – 10 mg/vessel 2.5\text{--}10\text{ mg/vessel} 2.5 – 10 mg/vessel ), Milrinone ( 4 – 8 mg 4\text{--}8\text{ mg} 4 – 8 mg ), or Verapamil ( 5 – 15 mg 5\text{--}15\text{ mg} 5 – 15 mg )

Durability Permanent / Durable mechanical dilation; rare recurrent vasospasm in dilated segment Transient effect ( 24 – 48 hours 24\text{--}48\text{ hours} 24 – 48 hours ) ; frequently necessitates repeat endovascular procedures

Procedural Risks Arterial dissection, vessel rupture ( 1 – 2 % 1\text{--}2\% 1 – 2% , often fatal), thromboembolism Systemic hypotension, intracranial hypertension (rebound ICP spike), transient seizure